Results

Total Results: 1,541 records

Showing results for "months".

21. Lumbar-Fusion-Draft-Report-Appendix-D (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/lumbar-fusion-draft-report-appendix-d.xlsx
    January 01, 2019 - B 8.2 months (3.2) vs. 9.1 months (4.1) 72 63% NR NR NR 3 months 6 months A vs. … months A vs. … B 10.7 months (5.22) vs. 11.3 months (5.05) 50 55.0% (33/60) NR NR NR 6 months A vs. … B 24.5 months (9.7) vs. 26.4 months (10.2) 56 45.0% (36/80) NR NR NR 6 months A vs. … ) 73 75% 23 NR NR 3 months, 6 months A vs.

22. Cannabis-2022-Surv-Rep-3-Table-F5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-table-F5.xlsx
    January 01, 2022 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

23. Cannabis-2022-Update-Surv-Rep-1-App-F-5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F-5.xlsx
    January 01, 2022 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

24. Intergrated and Comprehensive Pain Management Programs: Effectiveness and Harms: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-251-integrated-pain-management-evidence-summary.pdf
    October 01, 2021 - following treatment completion), intermediate term (≥6 to <12 months), and long term (≥12 months). … ) Small + No evidence No evidence Intermediate term (≥6 to <12 months) Small + No evidence … (≥12 months) None + None + None + Opioid Use (Effect Size/SOE)a Postintervention None … + None + Small + Moderatec + None + Long term (≥12 months) None + None ++ … ) None + None ++ Small ++ None + None + Long term (≥12 months) None + None +

25. Data Points 14: Use of Endocrine Therapy (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-endocrine-therapy_research.pdf
    August 01, 2012 - since diagnosis, 2007-2008ǂ 0-12 months 13-24 months 25-36 months 37-48 months 49-60 months … 13-24 months 25-36 months 37-48 months 49-60 months ER Status Not done 33.5 27.2 35.8 26.1 … since diagnosis, 2007- 2008ǂ 0-12 months 13-24 months 25-36 months 37-48 months 49-60 months … 13-24 months 25-36 months 37-48 months 49-60 months ER Status Not done 53.0 37.2 49.5 45.9 … since diagnosis, 2007- 2008ǂ 0-12 months 13-24 months 25-36 months 37-48 months 49-60 months

26. Template for Draft Reports (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
    October 06, 2006 - months 0.327 0.013 8.215 0.497 49 / 50 50 / 50 RITA* Survival 6 months 1.000 0.301 3.325 1.000 501 / … 12 months -0.012 -0.034 0.010 0.278 511 / 532 491 / 505 EAST Survival 12 months -0.020 -0.059 0.019 … 12 months 0.726 0.255 2.067 0.549 497 / 506 489 / 495 Seoul-Kim Survival 12 months 1.000 0.135 7.392 … 24 months Survival 24 months Survival 24 months Survival 24 months Survival 24 months Survival 24 months … MI 36 months MI 36 months MI 36 months EAST E G -0.15 -0.08 0.00 0.08 0.15 Fav ors CABG Fav

27. Clopidogrel after Drug-Eluting Stent Implantation: Is current practice sufficient (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/stent-clopidogrel-practice_research.pdf
    March 01, 2009 - were event-free 6 months after their initial stent procedure. … By 24 months, clopidogrel use had diminished among patients who reported using it at 6 months (Table … Our population included 2518 patients who were event-free at 12 months. … to be some crossover in patient-reported clopidogrel use between 6 and 12 months. … ) 0.003 Clopidogrel use at: 6 Months 637 (100) 0 (0) 417 (100) 0 (0) <0.001 12 Months 382 (72.9

28. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update - Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/noninvasive-nonpharm-pain-summary.pdf
    April 01, 2020 - ), intermediate term (≥6 to <12 months) and long term (≥12 months). … ), intermediate term (≥6 to <12 months) and long term (≥12 months). … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, small, moderate, or large … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, small, moderate, or large … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, small, moderate, or large

29. Lumbar-Fusion-Draft-Report-Appendix-E (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/lumbar-fusion-draft-report-appendix-e.xlsx
    January 01, 2023 - Yes Yes Yes Yes Yes Yes Yes Yes Moderate 6409 van Wijk, 2005 5-RFA Yes Yes Yes Yes Yes Yes Yes - 3 months … No - 6 months Yes - 3 months (100%) Unclear - 6 months Yes - 3 months No - 6 months Yes - 3 months No … - 6 months Yes Low 5569 Zhou, 2016 5-RFA Yes Unclear Yes Unclear Unclear Unclear No Unclear Unclear

30. Newly Medicare-Eligible Disabled: Data Points #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicare-eligible-disabled_research.pdf
    June 01, 2011 - Medicare-eligible disabled: comparison of duals and nonduals Among disabled individuals in the first six months … This report focuses on the first six months of Medicare eligibility for persons with disabilities, … We extracted all Medicare claims for the initial six months of eligibility for these individuals. … Partial Duals received State support for all six months in the form of premium or copayment assistance … 6 months of Medicare (%) 1.20 1.13 1.06 1.69 Survival during initial 6 months of Medicare (%) 98.80

31. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/mat-retention-strategies-rapid-review-1.pdf
    August 01, 2020 - MAT retention duration ranged from 3 to 24 months. … Engagement in outpatient buprenorphine treatment at 6 months 2. … Treatment retention in original OTP at 12 months 2. … Buprenorphine 12 months Retention: % of patients in program at 12 months Telehealth Intervention … " - stable Methadone 6 months in study; baseline mean 9 months in methadone Retention: % participants

32. Middle Ear Infections: What to Expect and Treatment Options (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ebc-challenge-3rdplace_tympanic.pdf
    May 29, 2025 - Pneumococcal polysaccharide protein conjugate vaccine (PCV7) should be administered in children aged 2–23 months …  Recurrent Otitis Media (ROM) is defined as three or more diagnosed occurrences of AOM within six months … or four episodes within 12 months (9) … Tympanostomy tube insertion can substantially reduce the rate of ear infections after the first six months … (More than 3 in 6 months, or 4 in 12 months) (9). Ear tubes help to: 1.

33. App-D-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
    September 30, 2015 - Pain > 3 months, currently prescribed opioids Exclusion: cancer and end-of-life treatment A. … B, at 3 months Pain intensity (0 to 10 NRS, mean change from baseline): -3.84 (2.08) vs. -4.73 (2.28 … Duration: Up to 12 months of followup Inclusion: 12 months of continuous opioid prescriptions of at least … medical and drug plan enrollment for minimum of 6 months in the pre period and up to 33 months in the … , 28.4 months followup E: Other opioids, continuing users (n=7,238), dose NR, 28.4 months followup F:

34. Newly Medicare-Eligible Elders: Data Points #12 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicare-utilization-seniors_research.pdf
    June 01, 2012 - Data Points #12 Newly Medicare-Eligible Elders Data Points # 12 Health care use in the first six months … This report examines the health care use and expenditures for the first six months of eligibility for … We included all Medicare claims for the initial six months of eligibility for these individuals. … While 6 percent of new enrollees received some form of State support during their first six months … This would explain the observed pat- tern of unequal Part A and Part B months.

35. Rapid Response_Linking Dental Services to Treatment Outcomes for Chronic Kidney Disease: A Rapid Response Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-outcomes-chronic-kidney-rapid-research.pdf
    November 01, 2024 - • Studies of minimum 3 months duration (it takes ~3 months for eGFR to stabilize) None Setting … • Cr (4 – 6 months) • No change • BUN (n=3) (2 – 4 months) • ↑ • CRP (n=3) • ↓ in all studies … evidence • Alb (3 – 6 months) • insufficient evidence • Lipids (3 – 6 months) • insufficient … ) • No change analysis performed for the other outcomes. • BUN (n=3) (2–4 months) • ↑ • CRP (n= … (Figure 3), and that most of the studies show a followup time of 6 months.

36. Heart-Failure-Transition-Care Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-transition-care_executive.pdf
    May 01, 2014 - 30 Days 3 to 6 Months 30 Days 3 to 6 Months 30 Days 3 to 6 Months Home-visiting programs … months 1; 106 0.66 (0.43 to 1.01) NA Insufficient Mortality 3 to 6 months 2; 264 0.59 (0.12 to 3.03) … Composite endpoint 3 to 6 months 2; 423 0.92 (0.58 to 1.47) NA Low Mortality 3 to 6 months 2; 423 … , or 6 months. … (low SOE) but not at 6 months (low SOE).

37. CER 45 Self-Measured Blood Pressure Monitoring Comparative Effectiveness Surveillance Final 4.7.16 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure-surveillance-160412.pdf
    May 29, 2025 - "12"months"when"compared"to"usual"care … "('6.0"mm"Hg,"p"<.001),"at"12"months"('5.1"mm"Hg,"p<.001),"and"at"18" months"('3.0"mm"Hg,"p"=".07)." … $and$a$trend$at$12$months. … $Secondary$outcomes$were$change$ in$BP,$patient$satisfaction,$and$BP$control$at$18$months$(6$months$ … $and$a$trend$at$12$ months.

38. App-E-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - 2020 India Head-to-Head Good NPP (DPN) Age, mean: 54.5 Female: 39.5% Race: NR Pain duration: 11.4 months … 64% Black: 16% Multiracial: 10% Asian: 3% Pacific Islander: 1% Race not known: 4% Pain duration: ≥6 months … Fair LBP Age, mean: 51 Female: 61% Race: Caucasian: 75% Hispanic: 19% Other: 7% Pain duration: 110 months … Egypt Fair Chronic pelvic pain Age, mean: 31.4 Female: 100% Race: NR Pain duration, median: 16.5 months … Age, mean: 30.3 Female: 100% Race: White: 97% Black: 0.3% Asian: 2% Mixed: 0.3% Pain duration: ≥3 months

39. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - After 3 months 88% achieved ACR Pedi 30. After 12 months, 76% did. … Active arthritis persisted at 1 month in 39%, at 3 months in 27%, at > 6 months in 11%. … duration Clinical inactive disease (CID) at 6 months 12 months At 6 months, 40% of patients in … after 27 months. … reached ID after 39 months.

40. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - After 3 months 88% achieved ACR Pedi 30. After 12 months, 76% did. … Active arthritis persisted at 1 month in 39%, at 3 months in 27%, at > 6 months in 11%. … duration Clinical inactive disease (CID) at 6 months 12 months At 6 months, 40% of patients in … after 27 months. … reached ID after 39 months.